Endothelial Cells Derived from the Blood-Brain Barrier and Islets of Langerhans Differ in their Response to the Effects of Bilirubin on Oxidative Stress Under Hyperglycemic Conditions by Jaime Kapitulnik et al.
ORIGINAL RESEARCH ARTICLE
published: 13 July 2012
doi: 10.3389/fphar.2012.00131
Endothelial cells derived from the blood-brain barrier and
islets of Langerhans differ in their response to the effects
of bilirubin on oxidative stress under hyperglycemic
conditions
Jaime Kapitulnik*, Clara Benaim and Shlomo Sasson
Department of Pharmacology, Institute of Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel
Edited by:
Hege Christensen, University of Oslo,
Norway
Reviewed by:
Nils Tore Vethe, Oslo University
Hospital, Norway
StanislavYanev, Department of Drug
Toxicology, Bulgaria
*Correspondence:
Jaime Kapitulnik, Department of
Pharmacology, Institute of Drug
Research, School of Pharmacy, The
Hebrew University of Jerusalem,
P.O.B. 12065, Ein Kerem, Jerusalem
91120, Israel.
e-mail: jaimek@savion.huji.ac.il
Unconjugated bilirubin (UCB) is a neurotoxic degradation product of heme. Its toxic effects
include induction of apoptosis, and ultimately neuronal cell death. However, at low concen-
trations, UCB is a potent antioxidant that may protect cells and tissues against oxidative
stress by neutralizing toxic metabolites such as reactive oxygen species (ROS). High glu-
cose levels (hyperglycemia) generate reactive metabolites. Endothelial cell dysfunction, an
early vascular complication in diabetes, has been associated with hyperglycemia-induced
oxidative stress. Both glucose and UCB are substrates for transport proteins in microvascu-
lar endothelial cells of the blood-brain barrier (BBB). In the current study we show that UCB
(1–40µM) induces apoptosis and reduces survival of bEnd3 cells, a mouse brain endothe-
lial cell line which serves as an in vitro model of the BBB.These deleterious effects of UCB
were enhanced in the presence of high glucose (25 mM) levels. Interestingly, the bEnd3
cells exhibited an increased sensitivity to the apoptotic effects of UCB when compared to
the MS1 microcapillary endothelial cell line. MS1 cells originate from murine pancreatic
islets of Langerhans, and are devoid of the barrier characteristics of BBB-derived endothelial
cells. ROS production was increased in both bEnd3 and MS1 cells exposed to high glucose,
as compared with cells exposed to normal (5.5 mM) glucose levels.While UCB (0.1–40µM)
did not alter ROS production in cells exposed to normal glucose, relatively low (“physiologi-
cal”) UCB concentrations (0.1–5µM) attenuated ROS generation in both cell lines exposed
to high glucose levels. Most strikingly, higher UCB concentrations (20–40µM) increased
ROS generation in bEnd3 cells exposed to high glucose, but not in similarly treated MS1
cells.These results may be of critical importance for understanding the vulnerability of the
BBB endothelium upon exposure to increasing UCB levels under hyperglycemic conditions.
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INTRODUCTION
Bilirubin is a linear tetrapyrrole that is formed during the process
of heme degradation. Heme is released from a series of hemepro-
teins, including hemoglobin and cytochromes P450, and metab-
olized by heme oxygenase to form carbon monoxide, biliverdin,
and free iron. Biliverdin is subsequently transformed to uncon-
jugated bilirubin (UCB) by biliverdin reductase. UCB binds to
plasma albumin, which transports it to the liver, where it is
conjugated to hydrophilic acceptors. The major conjugates are
bilirubin glucuronides formed by UDP-glucuronosyltransferase
1A1 (UGT1A1). These polar derivatives are thereafter excreted in
the bile (Figure 1).
Unconjugated bilirubin is a molecule which behaves as a
“double-edged sword” (Kapitulnik, 2004); it exerts both cytotoxic
and cytoprotective effects which are dose- and target-dependent.
When the blood levels of UCB are excessively elevated and sur-
pass the capacity of albumin for high-affinity binding of UCB, the
unbound (free) fraction of the pigment increases. Free UCB can
easily enter cells by passive diffusion and cause toxicity. The most
vulnerable target is the central nervous system (CNS). UCB binds
to discrete brain areas, such as the basal ganglia (kernicterus), and
produces a wide array of neurological deficits collectively known
as bilirubin encephalopathy.
The cytotoxic effects of UCB include programmed cell death
(apoptosis) of a variety of cell types such as neurons (Grojean
et al., 2000; Rodrigues et al., 2002), aortic smooth muscle cells
(Liu et al., 2002), brain microvascular endothelial cells (Akin et al.,
2002), and hepatoma cells (Seubert et al., 2002).
The pioneering studies conducted in the laboratory of Bruce
Ames (Stocker et al., 1987a,b) introduced the concept that UCB,
which was until then regarded as a toxic waste product of
heme catabolism, possesses a beneficial role at low (“physiolog-
ical”) plasma concentrations (<1 mg/dl, <17µM) by acting as a
potent antioxidant that scavenges reactive oxygen species (ROS).
Almost two decades ago it was suggested that moderately ele-
vated plasma UCB levels may reduce the risk of coronary artery
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FIGURE 1 | Formation and elimination of unconjugated bilirubin.
disease (Schwertner et al., 1994). Indeed, individuals with Gilbert
syndrome, a mild form of hyperbilirubinemia, who display mod-
erately increased plasma UCB concentrations (∼40µM) due to
a decreased UGT1A1 activity, show a lower risk of cardiovas-
cular and related diseases such as diabetes, as compared with
normobilirubinemic subjects (reviewed by Lin et al., 2010; Vitek,
2012).
High glucose (hyperglycemia) augments production of ROS,
which play a major role in the etiology of diabetes complica-
tions, such as endothelial dysfunction (Guzik et al., 2002) and
astrocyte activation in the CNS (Wang et al., 2012). Of inter-
est are the findings that ROS generated by hyperglycemia cause
apoptosis of vascular endothelial cells (Hulsmans et al., 2012) and
are responsible for the endothelial cell sloughing associated with
hyperglycemia (Rodella et al., 2006).
Glucose is an essential nutrient for brain cells and crosses the
blood-brain barrier (BBB) via the influx glucose transporter-1
(GLUT1). The entry of the neurotoxic UCB into the brain is pre-
vented by the efflux transporter P-glycoprotein (P-gp). Thus, it was
of great interest to examine the interplay between UCB and glucose
in BBB-derived endothelial cells. In the current study we exam-
ined the effects of low (“physiological”) and moderately elevated
UCB concentrations (0.1–40µM), alone or in combination with
high glucose, on apoptosis and cellular ROS levels in bEnd3 cells,
which are a model for studying BBB characteristics. The responses
of these cells to UCB and glucose were compared with those of
MS1 cells, microvascular endothelial cells derived from pancreatic
islets of Langerhans. The latter cells do not exhibit barrier charac-
teristics and may serve as a model for studying free glucose passage
into pancreatic islets.
MATERIALS AND METHODS
CHEMICALS
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum
(FBS), HEPES, SDS 10% (wt/vol) solution, l-glutamine solution
(2 mM), penicillin (100 U/ml) and streptomycin (0.1 mg/ml) solu-
tion, sodium pyruvate,and trypsin were purchased from Biological
Industries (Beth-Haemek, Israel). Micro BCA™protein assay kit,
bovine serum albumin (BSA; fraction V), DMSO, PBS, NaOH,
and staurosporine solution were purchased from Sigma-Aldrich
(Rehovot, Israel). UCB was purchased from MP Biomedicals
(Santa Ana, CA, USA), hydrogen peroxide 30% (wt/vol) from J.
T. Baker (Phillipsburg, NJ, USA), 5- (and 6-) chloromethyl-2′,7′-
dichlorodihydrofluorescein diacetate (CM-H2DCFDA) from Mol-
ecular Probes (Eugene, OR, USA), and D(+) glucose anhydrous
from Riedel-de Haën (Seelze, Germany).
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CELL CULTURE
The bEnd3 microvascular endothelial cell line is derived from
mouse brain. These cells display structural and functional bar-
rier properties owing to their high expression of tight junction
proteins and high transendothelial resistance, thus resembling the
BBB (Brown et al., 2007; Li et al., 2010). The MS1 microvascular
endothelial cell line is derived from mouse pancreatic islets. These
cells are highly fenestrated and do not show barrier characteristics
(Konstantinova and Lammert, 2004). The bEnd3 cells were a gift
from Dr. P. Lazarovici (School of Pharmacy, Hebrew University
of Jerusalem), and MS1 cells were purchased from American Type
Culture Collection (ATCC, Manassas, VA, USA).
Both cell types were grown in plastic flasks in DMEM cul-
ture medium supplemented with 1% (vol/vol) antibiotics, 1%
(vol/vol) l-glutamine, 10% (vol/vol) FBS, and 5.5 mM glucose
(37˚C, 5% CO2). After reaching confluency, cells were plated
to 12 well-plates in 2 ml of fresh culture medium per well.
The culture medium was replaced 24 h after seeding with fresh
medium containing 5.5 or 25 mM glucose. After an additional
24 h-incubation period, the culture medium was replaced with
fresh medium containing increasing concentrations of UCB. A
fresh stock solution of UCB (40 mM, in 0.1 M NaOH) was pre-
pared for each experiment. Serial dilutions of the UCB stock
solution were made in fresh culture medium containing 20 mM
HEPES, to keep a stable pH of 7.5–7.6, and 5.5 or 25 mM glu-
cose. Cells were further incubated for an additional 24 h-period.
Addition of UCB and further handling of cell cultures was done
in dim light.
CELL NUMBER DETERMINATION
Cells were detached from the plate with 0.25 ml of a solution
of trypsin (1:2000). Volume was adjusted to 0.5 ml with culture
medium and cells were counted in a hemacytometer.
APOPTOSIS
Apoptosis was assayed using the FAM-FLICA™Poly Caspases
Assay Kit (ImmunoChemistry Technologies, LLC, Bloomington,
MN, USA). This assay detects the presence of caspase activity in
apoptotic cells by quantifying the intensity of fluorescence in cells
exposed to a membrane-permeant, Fluorescent Labeled Inhibitor
of Caspases (FLICA) probe. The fluorescent tag is carboxyfluores-
cein. This probe binds covalently with the active caspases and is
retained only in apoptotic cells.
After incubation with increasing concentrations of UCB, the
cells were analyzed according to the manufacturer’s instruc-
tions. Briefly, cells were trypsinized, followed by centrifuga-
tion and resuspension in culture medium. Triplicate samples of
2.5× 106 cells from each treatment were transferred into plastic
tubes and incubated in the dark with the carboxyfluorescein-
FLICA solution for 1 h (37˚C, 5% CO2). Cell suspensions were
thereafter washed twice with wash buffer and resuspended in
PBS, keeping a final uniform cell density (2.5× 106 cells/sample).
One hundred microliters of each cell suspension was placed into
each of three wells of a black microtiter plate for measurement
of fluorescence intensity (excitation: 490 nm; emission: 520 nm).
Thus, triplicate readings were obtained for each triplicate cas-
pase sample. A positive control was prepared by incubating naive
(untreated) cells with 1µM staurosporine for 3 h. Staurosporine
induces apoptosis by caspase activation (Thuret et al., 2003).
Caspase activity was expressed as relative fluorescence units
(RFU), calculated by dividing the individual fluorescence values
for the different treatments by that obtained for cells exposed to
5.5 mM glucose in the absence of UCB (the latter were assigned a
value of 1). Experiments were repeated at least three times.
REACTIVE OXYGEN SPECIES
Reactive oxygen species production was examined using
the cell-permeant probe 5- (and 6-) chloromethyl-2′,7′-
dichlorodihydrofluorescein diacetate (CM-H2DCFDA). This dye
enters the cell by passive diffusion, undergoes hydrolysis to gen-
erate chloromethyl-dichlorodihydrofluorescein (CM-H2DCF),
which remains trapped intracellularly. Upon oxidation of
CM-H2DCF by ROS, the fluorescent product chloromethyl-
dichlorofluorescein (CM-DCF) is formed (Kehrer and Parai-
dathathu,1992). After incubation with UCB,cells were rinsed three
times with PBS and incubated with CM-H2DCFDA for 30 min
(37˚C, 5% CO2). The cells were thereafter washed three times with
PBS and solubilized with 600µl SDS 0.1% (wt/vol). One hundred
microliters of each sample was placed into each of three wells of
black microtiter plates, and fluorescence intensity was measured
(excitation: 490 nm; emission: 520 nm). A positive control was
prepared by incubating naive (untreated) cells with 1 mM H2O2
for 2 h.
Reactive oxygen species production was normalized to pro-
tein content. Twenty microliters aliquots of each sample were
placed into each of three wells of 96-multiwell plates. Volume was
adjusted to 150µl with SDS 0.1%, and 150µl of Micro BCA work-
ing reagent was added. The plates were covered and incubated for
2 h (37˚C, 5% CO2), and the colored product was quantitated by
measuring absorbance at 562 nm.
Reactive oxygen species production is expressed as RFU, calcu-
lated by dividing the individual fluorescence values for the differ-
ent treatments (normalized to protein content) by that obtained
for cells exposed to 5.5 mM glucose in the absence of UCB (the
latter were assigned a value of 1). Experiments were repeated at
least three times.
STATISTICAL ANALYSIS
The experiments were carried out in replicates of n≥ 3 and results
are presented as Mean± Standard Deviation. Statistical differ-
ences were evaluated using the Student’s two-tailed t test. A “p”
value of ≤0.05 indicates statistical significance.
RESULTS
APOPTOTIC EFFECTS OF BILIRUBIN AND/OR GLUCOSE
Confluent cultures of bEnd3 and MS1 cells were incubated for
48 h with culture medium containing normal (5.5 mM) or high
(25 mM) glucose, in the absence or presence of increasing concen-
trations of UCB added during the last 24 h of incubation. UCB
(1–40µM) caused a concentration-dependent increase of caspase
activity in both cell types (Figure 2). This effect was more pro-
nounced in bEnd3 than in MS1 cells. The 40µM concentration of
UCB caused a 7.6-fold increase in caspase activity in the normal
glucose-containing cultures (Figure 2A), as compared with a 2.5-
fold increase in MS1 cells under similar conditions (Figure 2B).
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FIGURE 2 | Apoptotic effects of UCB and glucose in microvascular
endothelial cells. Confluent cultures of bEnd3 (A) or MS1 (B) cells were
incubated for 48 h with culture medium containing normal (5.5 mM; -◦-) or
high (25 mM; -•-) glucose, in the absence or presence of increasing
concentrations of UCB added during the last 24 h of incubation. Caspase
activity was determined using the carboxyfluorescein-FLICA probe (see
Materials and Methods) and was expressed as relative fluorescence units
(RFU), calculated by dividing the individual fluorescence values for the
different treatments by that obtained for cells exposed to 5.5 mM glucose
in the absence of UCB (the latter were assigned a value of 1). Experiments
were repeated at least three times. The results of a representative
experiment are shown as Mean±Standard Deviation. Values for the bEnd
cells at all UCB concentrations differ from the values obtained in the
absence of UCB (statistically significant at p<0.05). Values for the MS1
cells at UCB concentrations of 10–40µM differ from the values obtained in
the absence of UCB (statistically significant at p<0.05).
Noteworthy, in contrast with the marked apoptotic effect of UCB
in bEnd3, but not in MS1 cells, exposure of both cell types to 1µM
staurosporine caused a 6.2-fold increase in caspase activity. Ele-
vation of the glucose concentration to 25 mM in the absence of
UCB, increased caspase activity nearly twofold in both cell types,
and further increased the effect of 40µM UCB to 9.3- and 4.5-fold
for bEnd3 and MS1 cells, respectively (Figures 2A,B). It should
be noted that the relative degree of apoptosis in high glucose-
containing bEnd3 cultures was more pronounced for the lower
(1–10µM) than for the higher (20–40µM) UCB concentrations
(Figure 2A). UCB also reduced the number of viable bEnd3 cells,
and high glucose increased this effect (Table 1). As described above
for the caspase activity determinations, the MS1 cells were also
less sensitive to the cytotoxic effects of UCB. The fraction of non-
viable/apoptotic cells was less than 1% for all treatments of both
cell lines (data not shown).
EFFECTS OF UCB ON THE GENERATION OF ROS IN ENDOTHELIAL CELLS
CULTURED IN NORMAL AND HIGH GLUCOSE-CONTAINING MEDIA
Given the differential sensitivity of bEnd3 vs. MS1 cells toward the
apoptotic effect of UCB, and the involvement of ROS in apoptosis
of endothelial cells, it was of a great interest to determine whether
these two cell types also differ in their capacity to produce ROS in
response to either UCB or high glucose, or to their combination.
Exposure of both bEnd3 and MS1 cells to increasing concen-
trations of UCB in normal glucose-containing medium had no
significant effect on ROS production (Figures 3A,B, respectively).
In the bEnd3 cells, elevation of the glucose concentration to 25 mM
approximately doubled ROS production in the absence of UCB.
Table 1 |Viability of microvascular endothelial cells exposed to UCB in
normal or high glucose-containing culture media.
UCB (µM) bEnd3 cells MS1 cells
5.5mM
glucose
25mM
glucose
5.5mM
glucose
25mM
glucose
0 100 100 100 100
10 94.5±1.0 91.6±1.7 94.8±1.6 95.1±3.5
40 85.0±0.7 77.5±2.1 90.3±1.0 84.5±0.5
Cells were counted at the end of incubations with UCB in normal (5.5mM) or high
(25mM) glucose-containing media.The fraction of non-viable/apoptotic cells was
less than 1% for all treatments of both cell lines (data not shown). Results are
expressed as percentages of viable cells, and are presented as Mean±Standard
Deviation of triplicate samples. Numbers of cells in the absence of UCB are taken
as 100% values: bEnd3 cells in normal glucose – 1.47×106 cells/ml; in high glu-
cose – 1.78×106 cells/ml. MS1 cells in normal glucose – 1.55×106 cells/ml; in
high glucose – 1.23×106 cells/ml.
The combined exposure of bEnd3 cells to UCB (0.1–40µM) and
high glucose had a biphasic effect on ROS production (Figure 3A).
UCB (0.1–5µM) caused an initial decrease in ROS production:
similar ROS values were obtained at 25 and 5.5 mM glucose in
the presence of 2µM UCB. Higher UCB concentrations (20–
40µM) markedly elevated ROS production in the presence of
25 mM glucose.
Exposure of MS1 cells to high glucose caused a minor ele-
vation in ROS production (about 40%) in the absence of UCB
(Figure 3B). Again, low (0.1–5µM) concentrations of UCB abol-
ished this increase, as shown for the bEnd3 cells. However, in
contrast to the latter cells, increasing further the UCB concen-
tration (up to 40µM) did not increase ROS production in MS1
cells above the value obtained in the absence of UCB. In a con-
trol experiment, 1 mM H2O2 caused 1.5- and 1.6-fold increases in
ROS production in bEnd3 and MS1 cells, respectively.
DISCUSSION
The CNS is extremely sensitive to UCB, particularly in the immedi-
ate postnatal period. UCB-induced neurotoxicity is affected by the
interplay between neurons and glial cells (Silva et al., 2011). Rela-
tively low UCB levels may cause apoptotic cell death, particularly
in immature neurons (Grojean et al., 2000; Rodrigues et al., 2002).
We show here that endothelial cells derived from the brain
microvasculature exhibit a marked and dose-dependent apop-
totic response to UCB, as compared with a weaker response of
microvascular endothelial cells obtained from pancreatic islets of
Langerhans. Apoptosis in the former cells occurs already at UCB
concentrations which are considered “physiological” in humans,
namely 1–10µM, and is accompanied by a reduction in the num-
ber of viable cells remaining in culture after a 24 h-exposure to
UCB. To our knowledge, this is the first report on a greater sen-
sitivity to UCB of brain-derived microvascular endothelial cells,
when compared with their counterparts in other microvessels.
The brain-derived bEnd3 cells are useful for studying BBB
function in vitro since they display structural and functional bar-
rier properties owing to their high expression of tight junction
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FIGURE 3 | Effects of UCB on the generation of ROS in microvascular
endothelial cells cultured in normal or high glucose-containing media.
Confluent cultures of bEnd3 (A) or MS1 (B) cells were incubated for 48 h
with culture medium containing normal (5.5 mM; -◦-) or high (25 mM; -•-)
glucose, in the absence or presence of increasing concentrations of UCB
added during the last 24 h of incubation. ROS production was assessed
using the cell-permeant probe CM-H2DCFDA, as described in Materials and
Methods. ROS production was normalized by determining protein content
and is expressed as relative fluorescence units (RFU), calculated by dividing
the individual fluorescence values for the different treatments by that
obtained for cells exposed to 5.5 mM glucose in the absence of UCB (the
latter were assigned a value of 1). Experiments were repeated at least
three times. The results of a representative experiment are shown as
Mean±Standard Deviation. *Statistically significant difference from 0µM
UCB at p<0.05.
proteins and high transendothelial resistance (Brown et al., 2007;
Li et al., 2010). Glucose enters these cells via the GLUT1 trans-
porter. In contrast, the MS1 cells are highly fenestrated and lack
barrier characteristics (Konstantinova and Lammert, 2004). Glu-
cose passage through pancreatic islet microvascular endothelium
is free and elicits the release of insulin from β-cells in a glucose
concentration-dependent manner.
Increasing the glucose concentration of the culture medium
from 5.5 to 25 mM in cultures of both endothelial cell types
approximately doubled the caspase activity in the absence of UCB.
The combination of a high glucose level and increasing UCB
concentrations further increased the apoptotic response of the
cells, suggesting that UCB and hyperglycemia induce apoptosis in
these cells by independent mechanisms. In developing rat brain
neurons, UCB facilitates glutamate-mediated apoptosis through
the activation of N -methyl-d-aspartate receptors (Grojean et al.,
2001) or by directly disrupting the integrity of the mitochondrial
membrane, thus inducing mitochondrial depolarization and Bax
translocation (Rodrigues et al., 2002). On the other hand, high
glucose-mediated apoptosis of vascular endothelial cells results
from increased ROS production (van den Oever et al., 2010;
Hulsmans et al., 2012).
Under normal glucose conditions (5.5 mM glucose) there was
no significant effect of UCB (0.1–40µM) on ROS production
in either cell type, suggesting that ROS are not responsible for
UCB-mediated apoptosis in microvascular endothelial cells. In
contrast, in the absence of UCB, high glucose levels induced a
2.1-fold increase in ROS production in the brain-derived cells and
a 1.4-fold increase in the islet-derived cells.
Most strikingly, the two cell types studied showed different pat-
terns of ROS production in response to the combined exposure to
UCB and high glucose (Figures 3A,B). Such an exposure of brain-
derived bEnd3 cells affected ROS production in a biphasic manner.
Low (“physiological”) concentrations of UCB (0.1–2µM) atten-
uated high glucose-induced ROS production, while higher UCB
concentrations markedly elevated ROS production under these
conditions (Figure 3A). A similar initial decrease in ROS pro-
duction was observed in the MS1 islet-derived cells exposed to
UCB and high glucose. In both cell types the levels of ROS pro-
duced at 10µM UCB resembled the ROS levels measured in the
absence of UCB. However, contrary to the bEnd3 cells, further
increases in UCB concentration did not cause further changes in
ROS production in the MS1 cells (Figure 3B).
Thus, in the presence of high glucose, which by itself is
an ROS generator, low UCB concentrations exhibit a protec-
tive effect by counteracting the excessive production of ROS in
microvascular endothelial cells. The bEnd3 cells responded to
higher UCB concentrations by exacerbating the high glucose-
mediated oxidative stress, whereas the MS1 cells tolerated well this
condition and did not increase further ROS production. These
disparate responses suggest that hyperglycemia might compro-
mise the function of the BBB during hyperbilirubinemia, while
islets of Langerhans are more resistant to hyperbilirubinemia, and
thus may preserve their insulin secreting capacity in response to
hyperglycemia. Interestingly, hyperbilirubinemic Gunn rats do not
develop diabetes in response to streptozotocin exposure, as com-
pared to normobilirubinemic animals (Fu et al., 2010). Moreover,
insulin secretion by the pancreatic islets was preserved in these
hyperbilirubinemic animals.
Our data suggest that UCB per se does not affect ROS pro-
duction in microvascular endothelial cells under normal glucose
conditions. However, although ROS production under high glu-
cose conditions was diminished by low UCB concentrations in
both microvascular cell types, UCB-mediated apoptosis of these
cells was not affected by this decrease in ROS production. These
findings support a general concept that as much as ROS play a key
role in inducing apoptosis, there are other pro-apoptotic factors
that act independently of the redox state of cells.
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